JP2021534185A5 - - Google Patents

Info

Publication number
JP2021534185A5
JP2021534185A5 JP2021507918A JP2021507918A JP2021534185A5 JP 2021534185 A5 JP2021534185 A5 JP 2021534185A5 JP 2021507918 A JP2021507918 A JP 2021507918A JP 2021507918 A JP2021507918 A JP 2021507918A JP 2021534185 A5 JP2021534185 A5 JP 2021534185A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
subject
composition according
statin
approximately
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021507918A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021534185A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/046710 external-priority patent/WO2020037153A1/en
Publication of JP2021534185A publication Critical patent/JP2021534185A/ja
Publication of JP2021534185A5 publication Critical patent/JP2021534185A5/ja
Pending legal-status Critical Current

Links

JP2021507918A 2018-08-17 2019-08-15 スタチン治療対象における末梢動脈血行再建の必要性を低減する方法 Pending JP2021534185A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862719404P 2018-08-17 2018-08-17
US62/719,404 2018-08-17
PCT/US2019/046710 WO2020037153A1 (en) 2018-08-17 2019-08-15 Methods of reducing the need for peripheral arterial revascularization in a statin-treated subject

Publications (2)

Publication Number Publication Date
JP2021534185A JP2021534185A (ja) 2021-12-09
JP2021534185A5 true JP2021534185A5 (cg-RX-API-DMAC7.html) 2022-08-22

Family

ID=69524891

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021507918A Pending JP2021534185A (ja) 2018-08-17 2019-08-15 スタチン治療対象における末梢動脈血行再建の必要性を低減する方法

Country Status (17)

Country Link
US (2) US20220362200A1 (cg-RX-API-DMAC7.html)
EP (1) EP3836914A4 (cg-RX-API-DMAC7.html)
JP (1) JP2021534185A (cg-RX-API-DMAC7.html)
KR (1) KR20210047312A (cg-RX-API-DMAC7.html)
CN (1) CN112912071A (cg-RX-API-DMAC7.html)
AU (2) AU2019321568B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021002884A2 (cg-RX-API-DMAC7.html)
CL (3) CL2021000400A1 (cg-RX-API-DMAC7.html)
EA (1) EA202190547A1 (cg-RX-API-DMAC7.html)
IL (1) IL280643A (cg-RX-API-DMAC7.html)
MA (1) MA52680A1 (cg-RX-API-DMAC7.html)
MX (1) MX2021001906A (cg-RX-API-DMAC7.html)
NI (1) NI202100009A (cg-RX-API-DMAC7.html)
PH (1) PH12021550328A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202101562UA (cg-RX-API-DMAC7.html)
TN (1) TN2021000028A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020037153A1 (cg-RX-API-DMAC7.html)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX377553B (es) 2009-04-29 2025-03-10 Amarin Pharma Inc Composicion farmaceutica estable y metodos de uso de la misma.
CN107233337A (zh) 2009-04-29 2017-10-10 阿马里纳药物爱尔兰有限公司 含有epa和心血管剂的药物组合物以及使用其的方法
BRPI1011883A2 (pt) 2009-06-15 2016-09-13 Amarin Pharma Inc uso de composições para redução de triglicerídeos sem elevar os níveis de o ldl-c em um paciente sob o tratamento concomitante com estatina
NZ599061A (en) 2009-09-23 2014-05-30 Amarin Pharmaceuticals Ie Ltd Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
NZ744990A (en) 2010-11-29 2019-10-25 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
EP2800469B1 (en) 2012-01-06 2021-08-25 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject
US9603826B2 (en) 2012-06-29 2017-03-28 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
WO2014074552A2 (en) 2012-11-06 2014-05-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
WO2015195662A1 (en) 2014-06-16 2015-12-23 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
US10966951B2 (en) 2017-05-19 2021-04-06 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
US12430998B2 (en) 2018-09-14 2025-09-30 Avive Solutions, Inc. Device based responder network activation and virtual assistant integration
US11640755B2 (en) 2018-09-14 2023-05-02 Avive Solutions, Inc. Real time defibrillator incident data
US11645899B2 (en) 2018-09-14 2023-05-09 Avive Solutions, Inc. Responder network
MA50490A (fr) 2018-09-24 2020-09-02 Amarin Pharmaceuticals Ie Ltd Procédés de réduction du risque d'événements cardiovasculaires chez un sujet
CA3160676A1 (en) 2019-11-12 2021-05-20 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of cardiovascular events in a subject with atrial fibrillation and/or atrial flutter
US20210153817A1 (en) * 2019-11-21 2021-05-27 Avive Solutions, Inc. Device based responder network activation and virtual assistant integration
US11986452B2 (en) 2021-04-21 2024-05-21 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure
EP4329742A4 (en) * 2021-04-29 2025-02-26 Amarin Pharmaceuticals Ireland Limited COMPOSITIONS COMPRISING EPA AND METHODS OF USE THEREOF FOR TREATING AND/OR PREVENTING ENDOTHELIAL DYSFUNCTION IN A SUBJECT

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090239927A1 (en) * 2004-12-06 2009-09-24 George Bobotas Statin and Omega-3 Fatty Acids For Lipid Therapy
JP2009544701A (ja) * 2006-07-21 2009-12-17 リライアント・ファーマシューティカルズ・インコーポレイテッド オメガ3脂肪酸を含む組成物、ならびに末梢動脈障害および間欠性跛行を処置するためのそれらの使用
US9603826B2 (en) * 2012-06-29 2017-03-28 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
US20140322314A1 (en) * 2013-04-29 2014-10-30 Matinas Biopharma, Inc. Omega-3 Fatty Acid Formulations for Use as Pharmaceutical Treatment
CN114558129A (zh) * 2014-03-17 2022-05-31 赛诺菲生物技术公司 用于降低心血管风险的方法
US10406130B2 (en) * 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
PT3275438T (pt) * 2016-07-29 2021-01-25 Kowa Co Métodos de prevenção de eventos cardiovasculares em populações dislipidémicas de risco residual

Similar Documents

Publication Publication Date Title
US11179362B2 (en) Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
JP2020128412A5 (cg-RX-API-DMAC7.html)
HRP20210686T1 (hr) Pripravci i postupci za liječenje moždanog udara kod subjekta na istodobnoj terapiji statinom
US10966951B2 (en) Compositions and methods for lowering triglycerides in a subject having reduced kidney function
US20200268702A1 (en) Methods of treating hypertriglyceridemia
CA3008079C (en) Use of eicosapentaenoic acid to treat hypertriglyceridemia
US20200108041A1 (en) Methods of reducing ldl-p
US20140221676A1 (en) Compositions and methods for treating and/or preventing cardiovascular disease
US20150250757A1 (en) Methods for treating hypertriglyceridemia
US20140004183A1 (en) Methods for treating cardiovascular disease in statin-tolerant subjects
Nissen When is a placebo not a placebo
ES2524596T3 (es) Tratamiento a largo plazo de la insuficiencia cardiaca sintomática
Savelieva et al. Polyunsaturated fatty acids for prevention of atrial fibrillation: a ‘fishy'story
TH2101000853A (th) องค์ประกอบสำหรับใช้ในการลดความจำเป็นสำหรับการมีเลือดมาเลี้ยงใหม่ที่หลอดเลือดแดงส่วนปลายในผู้รับการทดลองที่ได้รับการรักษาด้วยสแตติน
HK40036364A (en) Compositions comprising eicosapentaenoic acid for treating myocardial infarction in a subject on concomitant statin therapy
Mihaiu et al. Experimental Studies on Guinea Pig Regarding the Influence of Polyunsaturated Fatty Acids as Enhancer in Statin Medication
AU2016231552A1 (en) Use of eicosapentaenoic acid ethyl ester for treating hypertriglyceridemia
HK1169838A (en) Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
HK1169838B (en) Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
HK1203764B (en) Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject